#Epistaxis Treatment Market | Explore Tumblr posts and blogs

distinguishedruinsfart · 5 days ago

Text

The Epistaxis Treatment Market sector is undergoing rapid transformation, with significant growth and innovations expected by 2028. In-depth market research offers a thorough analysis of market size, share, and emerging trends, providing essential insights into its expansion potential. The report explores market segmentation and definitions, emphasizing key components and growth drivers. Through the use of SWOT and PESTEL analyses, it evaluates the sector’s strengths, weaknesses, opportunities, and threats, while considering political, economic, social, technological, environmental, and legal influences. Expert evaluations of competitor strategies and recent developments shed light on geographical trends and forecast the market’s future direction, creating a solid framework for strategic planning and investment decisions.

Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-epistaxis-treatment-market

Which are the top companies operating in the Epistaxis Treatment Market?

The report profiles noticeable organizations working in the water purifier showcase and the triumphant methodologies received by them. It likewise reveals insights about the share held by each organization and their contribution to the market's extension. This Global Epistaxis Treatment Market report provides the information of the Top Companies in Epistaxis Treatment Market in the market their business strategy, financial situation etc.

Novartis AG, Noramco, Mallinckrodt, Johnson & Johnson Health Care Systems Inc., Teva Pharmaceuticals USA, Inc., Camber Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC, Lannett, Takeda Pharmaceutical Company Limited, Zydus Cadila, Par Pharmaceutical, Aurobindo Pharma USA, AdvaCare Pharma, Pfizer Inc., Angiplast, Sterimed Group, Cardinal Health, Elanor Surgicals, hitecmed, B.F. ASCHER & CO., INC., Bayer, Smith & Nephew

Report Scope and Market Segmentation

Which are the driving factors of the Epistaxis Treatment Market?

The driving factors of the Epistaxis Treatment Market are multifaceted and crucial for its growth and development. Technological advancements play a significant role by enhancing product efficiency, reducing costs, and introducing innovative features that cater to evolving consumer demands. Rising consumer interest and demand for keyword-related products and services further fuel market expansion. Favorable economic conditions, including increased disposable incomes, enable higher consumer spending, which benefits the market. Supportive regulatory environments, with policies that provide incentives and subsidies, also encourage growth, while globalization opens new opportunities by expanding market reach and international trade.

Epistaxis Treatment Market - Competitive and Segmentation Analysis:

North America, particularly the United States, will continue to exert significant influence that cannot be overlooked. Any shifts in the United States could impact the development trajectory of the Epistaxis Treatment Market. The North American market is poised for substantial growth over the forecast period. The region benefits from widespread adoption of advanced technologies and the presence of major industry players, creating abundant growth opportunities.

Similarly, Europe plays a crucial role in the global Epistaxis Treatment Market, expected to exhibit impressive growth in CAGR by 2028.

Explore Further Details about This Research Epistaxis Treatment Market Report https://www.databridgemarketresearch.com/reports/global-epistaxis-treatment-market

Key Benefits for Industry Participants and Stakeholders: –

Industry drivers, trends, restraints, and opportunities are covered in the study.

Neutral perspective on the Epistaxis Treatment Market scenario

Recent industry growth and new developments

Competitive landscape and strategies of key companies

The Historical, current, and estimated Epistaxis Treatment Market size in terms of value and size

In-depth, comprehensive analysis and forecasting of the Epistaxis Treatment Market

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical data and forecast (2024-2028) of the following regions are covered in Chapters

The countries covered in the Epistaxis Treatment Market report are U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, and Rest of the Middle East and Africa

Detailed TOC of Epistaxis Treatment Market Insights and Forecast to 2028

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Epistaxis Treatment Market Landscape

Part 05: Pipeline Analysis

Part 06: Epistaxis Treatment Market Sizing

Part 07: Five Forces Analysis

Part 08: Epistaxis Treatment Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Epistaxis Treatment Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Browse Language Based Reports:

https://www.databridgemarketresearch.com/jp/reports/global-epistaxis-treatment-market

https://www.databridgemarketresearch.com/zh/reports/global-epistaxis-treatment-market

https://www.databridgemarketresearch.com/pt/reports/global-epistaxis-treatment-market

https://www.databridgemarketresearch.com/de/reports/global-epistaxis-treatment-market

https://www.databridgemarketresearch.com/fr/reports/global-epistaxis-treatment-market

https://www.databridgemarketresearch.com/es/reports/global-epistaxis-treatment-market

https://www.databridgemarketresearch.com/ko/reports/global-epistaxis-treatment-market

https://www.databridgemarketresearch.com/ru/reports/global-epistaxis-treatment-market

Data Bridge Market Research:

Today's trends are a great way to predict future events!

Data Bridge Market Research is a market research and consulting company that stands out for its innovative and distinctive approach, as well as its unmatched resilience and integrated methods. We are dedicated to identifying the best market opportunities, and providing insightful information that will help your business thrive in the marketplace. Data Bridge offers tailored solutions to complex business challenges. This facilitates a smooth decision-making process. Data Bridge was founded in Pune in 2015. It is the product of deep wisdom and experience.

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 977

Email:- [email protected]

#Epistaxis Treatment Market #Epistaxis Treatment Market size #Epistaxis Treatment Market scope

0 notes

0healthcare1 · 3 months ago

Link

0 notes

factmrps · 2 years ago

Text

Global Epistaxis Market Outlook (2022 to 2032)

The global epistaxis market is evaluated at USD 193.5 Million in 2022 and is forecast to outshine USD 332.0 Million by 2032, mounting at a CAGR of 5.5% from 2022 to 2032.

Global epistaxis market is holding nearly 1% market share in global ear nose and throat (ENT) treatment market which is likely to grow at a CAGR of 6% during the forecast years.

For More Insights Into The Market, Request A Sample Of This Report:

The readability score of the Epistaxis Market Demand report is good as it offers chapter-wise layout with each section divided into a smaller sections.

The report encompasses graphs and tables to show the entire assembling. Pictorial demonstration of the definite and estimated values of key segments is visually appealing to readers.

This Epistaxis market outlook report explicates on vital dynamics such as the drivers, restraints and opportunities for key players and competitive analysis of Epistaxis along with key stakeholders as well as emerging players associated with the manufacturing of product.

Competitive Landscape: Top Companies in Epistaxis Market

To recover diffusion across profitable markets, the aforementioned players use various organic and inorganic strategies. Product launches, alliances and agreements with key epistaxis suppliers, acquisitions, and geographical expansion are all part of these strategies.

Fact.MR has provided detailed information about price points of top providers in epistaxis market positioned across regions, sales growth, production capacity, and speculative technological expansion in the recently published report.

For instance:

In August 2021, the company Pfizer Inc. has signed an agreement to acquire Trillium Therapeutics Inc., this acquisition will help company to strengthen the company’s presence in global market

In January 2022, Ascend Wellness Holdings has signed a partnership agreement with Siemens Healthineers, to expand the its testing capacity in the Ascend’s new laboratory in California

For In-Depth Competitive Analysis, Buy Now:

How will be insights and market estimations provided in the report on the Demand of Epistaxis make a difference?

The study takes a closer look at the major economic turmoil, with a focus on the recent COVID-19 pandemic disruptions

The assessment of key growth dynamics highlights the attractiveness of new automation technologies and offers readers insight on the prospect of these during the forecast period

The study tries to offer a balance perspective of the opportunities in mature and the most lackluster markets

Provides scrutiny of the industry trends that have shaped recent government policies

Provides an account of major breakthroughs in all segments that might change the course of the market considerably

Provides an incisive analysis of socio-political milieu in which the key markets operate, and how will that influence the lucrativeness of the overall Epistaxis Market

Analyzes how collaborations and partnerships among players from different industries shape the key growth dynamics in the near future

Evaluates the role of various stages of funding on new growth avenues in key regional markets

Contact: US Sales Office : 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E-Mail: [email protected]

0 notes

seolinkbiulding · 2 years ago

Text

#Martsolf Syndrome Treatment Market Share #Martsolf Syndrome Treatment Market size #Martsolf Syndrome Treatment Market trends #Martsolf Syndrome Treatment Market forecast

0 notes

mangeshgorade · 3 years ago

Text

Global Nosebleeds Market, Treatment Type (Vasoconstrictors, Anesthetics, Antibiotic Ointments, Cauterizing Agents, Others), Route of Administration (Oral, Intranasal, Others), Indication (Posterior Epistaxis, Anterior Epistaxis), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

#Nosebleeds_Market_Size #Nosebleeds_Market_Share #Nosebleeds_Market_Trends #Nosebleeds_Market_Growth #Nosebleeds_Market_Demand #Nosebleeds_Market_Analysis

0 notes

healthcare-market · 3 years ago

Text

Orogastric Devices Market Estimated to Observe Technological Advancements Further

Orogastric Devices Market: Introduction

· Orogastric devices are small tubes placed either through the mouth and the end with the tip in the stomach, or placed through the nose as per requirement. NG/OG (Nasogastric/Orogastric) tubes may be used for feedings, medication administration, or removal of contents from the stomach via aspiration, suction, or gravity drainage.

Request a Sample of Orogastric Devices Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=80940

· Generally, the patient is given an orogastric tube in cases where specially prepared liquid food or fluids are required to be fed directly into the stomach. Orogastric tube is used in case of issues with sucking and swallowing, dehydration from vomiting/diarrhoea and not drinking enough, lack of nutrition through the normal diet, or the patient is unable to swallow the medications. In some cases, it is also used to empty the contents of the patient’s stomach, including stomach gases. The tube is inserted by an experienced pediatric surgeon directly through the mouth and into the stomach.

· Orogastric tube placement is a common procedure routinely used in clinical anesthesiology and intensive care medicine. It is usually performed by only experienced doctors or nurses. It is also suggested to withdraw the tube promptly into the oropharynx if the patient has excessive choking, gagging, coughing, a change in voice, or the appearance of condensation on the inner aspect of the tube.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=80940

Key Drivers, Restraints, and Opportunities of Global Orogastric Devices Market

· Increase in incidence of diseases among infants, which makes them weak, is a major cause for the rise in preference for orogastric devices as a feeding tool, which is a key factor driving the global orogastric tube market

· Caustic ingestion or oesophageal strictures (risk of perforation), coagulopathy (epistaxis risk), base of skull fracture, severe mid-face trauma are a few rare occurring conditions of using the orogastric tube

· Slit endotracheal tubes, a new type of gastric tube guide (VBM Medizintechnik GmbH, Sulz, Germany), has been designed to facilitate the insertion of orogastric devices. The device is made of polyvinyl chloride. This is estimated to create further opportunity for global orogastric tube market.

Request for Analysis of COVID19 Impact on Orogastric Devices Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=80940

North America to Capture Major Share of Global Orogastric Devices Market

· The U.S. held a major share of the global orogastric tube market due to the awareness among people about the use of orogastric devices, which in turn drives the orogastric devices market

· The orogastric devices market in Asia Pacific is estimated to expand at a prominent pace due to an increase in birth rate. Furthermore, maternal malnutrition in low income countries in the region lead to the birth of infants with issues that require orogastric tube for the purpose of feeding.

Enquiry before Buying Orogastric Devices Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=80940

Key Players Operating in Orogastric Devices Market

The global orogastric Devices Market is highly fragmented, with the presence of various key players. A large number of manufacturers hold a major share in their respective regions.

More Trending Reports by Transparency Market Research:

Basal Cell Carcinoma Treatment Market The increase in geriatric population, who are highly susceptible to several types of skin diseases, such as actinic keratosis and various other non-melanoma skin malignancies, is also boosting the growth of the global basal cell carcinoma treatment market, reports the research study.

Refurbished Dental Equipment & Maintenance Market In terms of equipment, the global market has been classified into X-ray systems, cone beam computed tomography (CBCT) systems, intraoral scanners & cameras, dental lights, dental chairs, dental handpieces, chairside CAD/CAM systems, and others.

Surgical Masks Market North America dominated the global surgical masks market in 2020 and the trend is projected to continue during the forecast period. This can be ascribed to rapidly increasing number of COVID-19 cases in the U.S. and government & regulatory policies regarding manufacture as well as import of surgical masks.

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Mr. Rohit Bhisey Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: [email protected]

Website: https://www.transparencymarketresearch.com/

0 notes

jayu123-me · 3 years ago

Text

Petroleum jelly market expected to reach US$ 716.9 Mn by 2031

Petroleum Jelly Market: Introduction

Transparency Market Research delivers key insights on the global petroleum jelly market. In terms of value, the global petroleum jelly market is expected to expand at a CAGR of 4.26% during the forecast period, owing to numerous factors regarding which TMR offers thorough insights and forecasts in its report on the global petroleum jelly market.

Petroleum jelly is used in the treatment of epistaxis. It is also used in skin care and hair care products. Petroleum jelly is also used in hair pomades, which keep the hair shiny. In industrial appliances, petroleum jelly is used as an anticorrosion coat on metallic trinkets, non-stainless steel blades, and gun barrels. Petroleum jelly can be used as a finishing coat on wood and smooth leather products, owing to its water repellent properties. In industrial production processes, petroleum jelly is utilized as a release agent for plaster molds and castings. It can also be used as a waterproofing cream in the leather industry. Furthermore, petroleum jelly is utilized as a tack reducer additive in paper printing inks.

Petroleum Jelly Market: Dynamics

Petroleum jelly can be used in various applications that serve the purpose of metal protection as well as lubrication for machinery used in food preparation. Thus, petroleum jelly enhances food production standards. Petroleum jelly can be used as a release agent for plaster molds and castings. It can be used as a mold release agent for simple molds without fine details. The jelly can be directly applied by the hand. Thus, petroleum jelly can be a cost effective alternative to other traditional mold release agents.

Get Brochure of the Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=72726

Petroleum jelly can be used as a battery terminal compound. It protects battery terminals from corrosion when applied on the cable clamps and battery terminals. The hydrophobic nature of petroleum jelly enables it to act as a barrier to moisture. It also keeps battery terminals free from dirt, thus helping retain battery in good condition. The emergence of electric vehicles to reduce the global carbon footprint and encouragement by governments in the form of incentives for the purchase of e-vehicles are anticipated to boost the demand for batteries, thus propelling the petroleum jelly market during the forecast period.

Petroleum Jelly Market: Prominent Regions

North America is a key region of the global petroleum jelly market. The U.S. held large share of the petroleum jelly market in North America in 2020. The growth of the market in the country can be ascribed to the expansion of the cosmetic industry. The increase in the use of personal care and skincare products in the U.S. is driving cosmetics industry. According to the Forbes magazine, the U.S. was the world’s largest beauty market in 2020.

Request for Covid-19 Impact Analysis :

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=72726

Women in the U.S. spend around US$ 3,756 on cosmetics annually. Petroleum jelly is a vital ingredient used in the manufacture of skincare, personal care and hair care products. Petroleum jelly keeps the skin hydrated and enhances its health. Thus, the rise in the demand for cosmetics products is expected to boost the consumption of petroleum jelly.

The rapid growth of the petroleum jelly market in Europe is driven by the expansion of the electronic vehicles market. The implementation of stringent regulations on reduction of carbon footprint has driven the purchase of electronic vehicles. Electronic vehicles use batteries to store energy. This helps eliminate the need of traditional gasoline fuel, thus eliminating the emission of hydrocarbons. As battery terminal compound, petroleum jelly protects battery terminals from corrosion, dirt, and moisture, thus increasing the service life of batteries.

Enquiry before buying :

https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=72726

Harsh weather conditions in Europe are driving the demand for skincare products. Petroleum jelly helps retains the moisture in the skin, thus protecting the skin from becoming dry. Thus, rise in usage of petroleum jelly as a moisturizing agent and battery terminal compound is anticipated to boost the demand for petroleum jelly in the region.

The increase in demand for petroleum jelly in Asia Pacific can be ascribed to the rise in consumption of petroleum jelly as a cable filling compound in the region. Petroleum jelly is used as cable filling compound in fiber optic cables as well as traditional copper cables. It eliminates the formation of moisture in the cables, thus improving their service life. According to the IBEF (Indian Brand Equity Foundation), in the 2021-2022 Union Budget, the Government of India allocated US$ 1.9 Bn for the development of telecom infrastructure, which includes completion of optical fiber cable-based network for defense services. Thus, increase in investment in the telecom infrastructure in Asia Pacific is anticipated to boost the petroleum jelly market in the region during the forecast period.

Petroleum Jelly Market: Key Players

Key players operating in the global petroleum jelly market are Royal Dutch Shell, Sonneborn LLC, Sasol, Raj Petro Specialities Pvt. Ltd., Eastern Petroleum, Eastern Petroleum, Sovereign Chemicals & Cosmetics, Unisynth Group, Shimi Taghtiran Co., Nippon Siero Co., Ltd., and Petrobras.

More Trending Report by Transparency Market Research –

https://www.prnewswire.com/news-releases/antimicrobial-coatings-market-to-expand-at-cagr-of-12-1-during-forecast-period-notes-tmr-study-301479539.html

About Us:

Contact

Rohit Bhisey Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: [email protected] Website: https://www.transparencymarketresearch.com

0 notes

distinguishedruinsfart · 5 days ago

Text

0 notes

aparnasonali-blog · 6 years ago

Text

Haemophilia Market is projected to display CAGR of 6.84% during 2018 -2023

According to ACQUIRE MARKET RESEARCH Analytics research report “Global Haemophilia Market - Analysis By Type (Haemophilia A, Haemophilia B), By Treatment (On-demand, Prophylaxis), By Region, By Country (2019 Edition): Opportunities and Forecasts (2013-2023) By Region (North America, Europe, Asia-Pacific, Rest of the World), By Country (U.S, Canada, Germany, United Kingdom, Japan, China, India, Brazil)” , the global Haemophilia market is projected to display a modest growth represented by a CAGR of 6.84% during 2018 -2023.

Get Sample Copy @ https://www.acquiremarketresearch.com/sample-request/1503

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Haemophilia Market. The market of Global Haemophilia has been analyzed By Type (Haemophilia A, Haemophilia B), By Treatment (On-demand, Prophylaxis), By Region (North America, Europe, Asia Pacific, Rest of the world) and By Country (U.S, Canada, Germany, U.K, Japan, China, India and Brazil). The Global Haemophilia market has been assessed for the historical period of 2013-2017 and the forecast period of 2018-2023.

Over the recent years, global haemophilia market has been witnessing growth, on account of several driving factors including increasing life expectancy of hemophiliac patients, reduction in inhibitor formation in severe haemophilia cases and new emerging therapies for treatment of haemophilia. Moreover, increasing per capita healthcare expenditure and growing incidences of hemorrhages, arthropaedic and dental surgeries, epistaxis, laceration and abrasion is expected to propel the demand for haemophilia market. In this research report, the market is segmented on the basis of type and treatment. By type, the segment of haemophilia A is predicted to hold its dominant position in the market. Amongst the regions, North America accounts for the largest regional share in the global endoscopy devices market in 2018. However, Asia Pacific is predicted to advance at the highest rate. Presence of vast consumer base, particularly in emerging nations such as China and India, in addition to growing per capita expenditure on healthcare is likely to drive the regional market.

The report titled “Global Haemophilia Market, By Type (Haemophilia A, Haemophilia B), By Treatment (On-demand, Prophylaxis), By Region, By Country (2019 Edition): Opportunities and Forecasts (2013-2023) By Region (North America, Europe, Asia-Pacific, Rest of the World), By Country (U.S, Canada, Germany, United Kingdom, Japan, China, India, Brazil)”| has covered and analyzed the potential of global haemophilia market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global haemophilia market. Additionally, the report also highlights market entry strategies for various companies across the globe.

More info and TOC @ https://www.acquiremarketresearch.com/industry-reports/global-haemophilia-market-analysis-by-type-haemophilia/1503/

Scope of the Report

Global Haemophilia Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)

Haemophilia Market Size, Growth, Forecast

By Type Haemophilia A, Haemophilia B

By Treatment On- demand, Prophylaxis

Regional Markets North America, Europe, Asia-Pacific, ROW (Actual Period: 2013-2017, Forecast Period: 2018-2023)

Haemophilia Market Size, Growth, Forecast

By Type Haemophilia A, Haemophilia B

By Treatment On- demand, Prophylaxis

Country Analysis U.S., Canada, Germany, U.K, Japan, India, China, Brazil (Actual Period: 2013-2017, Forecast Period: 2018-2023)

Haemophilia Market Size, Growth, Forecast

By Type Haemophilia A, Haemophilia B

By Treatment On- demand, Prophylaxis

Other Report Highlights

Market Dynamics Drivers and Restraints

Market Trends

Company Share Analysis

SWOT Analysis

Porter Five Force Analysis

Supply Chain Analysis

Competitive Landscape

Policy and Regulatory Landscape

Company Analysis Bayer, Novo Nordisk, Pfizer, Roche, Aptevo Therapeutics, Catalyst Bio Sciences, Dimension Therapeutics, Shire, CSL Behring, Alnylam Pharmaceuticals .

Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Haemophilia Outlook

5. Global Haemophilia Market: Growth and Forecast

5.1 By Value (2013-2017)

5.2 By Value (2018-2023)

6. Global Haemophilia Market: Segment Analysis

6.1 Global Haemophilia Market Size, By Type: Breakdown (%)

6.1.1 Global Haemophilia Market Size, By Type, 2017 (%)

6.1.2 Global Haemophilia Market Size, By Type, 2023 (%)

6.2 Global Haemophilia A Market, By Value (2013-2023)

6.3 Global Haemophilia B Market, By Value (2013-2023)

About Acquire Market Research:

Acquire Market Research is a shrine of world-class research reports from around the world and we offer you only the best in the Industry when it comes to research. At Acquire, every data need will be catered to and met with a powerful world of choices.

“We understand the integral role data plays in the growth of Business empires.”

555 Madison Avenue,

5th Floor, Manhattan,

New York, 10022 USA

Phone No.: +1 (800) 663-5579

Email ID: [email protected]

#Haemophilia Market is projected to display CAGR of 6.84% during 2018 -2023

0 notes

greatestlcve · 4 years ago

Text

caduet tablets Uses, Dosage, Side Effects, Precautions & Warnings

Drug Online

caduet Generic drug of the Therapeutic class: Cardiology and angiology Active ingredients: Amlodipine , Atorvastatin

what is caduet medication?

This medication is supplied as blue, oval-shaped, film-coated tablets debossed with “Pfizer” on one side and “CDT 101” on the other side.

Boxes of 7, 10, 14, 20, 28, 30, 50, 56, 60, 90, 100 or 200 tablets.

Not all presentations may be marketed.

what is caduet medication used for and indication?

CADUET is indicated for the prevention of cardiovascular events in hypertensive patients with 3 associated cardiovascular risk factors, with normal to moderately elevated cholesterol without established coronary artery disease, and in whom, according to current recommendations, the concomitant use of amlodipine and a low dose of atorvastatin is suitable .

CADUET should be used when the response to regimen and other non-pharmacological measures is inadequate.

caduet dosage

Oral route

The usual starting dose is 5 mg / 10 mg once daily.

If tighter blood pressure control is required, a dosage of 10 mg / 10 mg once daily may be administered.

The tablets can be taken at any time of the day, with or without food.

CADUET can be used alone or in combination with other antihypertensive drugs, but it must not be used in combination with other calcium channel blockers or another statin.

The combination of CADUET and fibrates should generally be avoided (see sections 4.4 and Interactions with other medicinal products and other forms of interaction ).

Patients with renal impairment : No dosage adjustment is necessary in patients with impaired renal function (see sections 4.4 and Pharmacokinetic properties ).

Patients with hepatic impairment : CADUET is contraindicated in patients with active hepatic disease.

Children / Adolescents : The safety and efficacy of CADUET have not been established in children / adolescents. Therefore, the use of CADUET is not recommended in this population.

Elderly : It does not appear necessary to adjust the dose in the elderly (see section Pharmacokinetic properties ).

Combination with other medicinal products : In combination with ciclosporin, the dose of atorvastatin should not exceed 10 mg (see section Interactions with other medicinal products and other forms of interaction ).

Contraindications

CADUET is contraindicated in patients:

Being hypersensitive to dihydropyridines *, to amlodipine, to atorvastatin or to any of the excipients of this medicine,

have active liver disease or a persistent and unexplained increase in serum transaminases exceeding 3 times the upper limit of normal,

In women who are pregnant, breastfeeding or of childbearing potential and not using reliable contraceptive methods (see section Pregnancy and breast-feeding ),

In combination with itraconazole, ketoconazole, telithromycin (see section Interactions with other medicinal products and other forms of interactions ),

having severe hypotension,

Having shock (including cardiogenic shock),

Having an obstruction of the efferent pathway to the left ventricle (for example severe aortic stenosis),

With haemodynamically unstable heart failure after acute myocardial infarction.

* amlodipine is a calcium channel blocker derived from dihydropyridine.

HOW TO TAKE CADUET?

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if in doubt.

Adults

The recommended starting dose of CADUET is one 5 mg / 10 mg tablet per day. Your doctor may increase the dose if necessary to 1 tablet of CADUET 10 mg / 10 mg per day.

The tablets should be swallowed whole with a glass of water. They can be taken at any time of the day, with or without food. However, it is best to take them at the same time each day.

Continue to follow your doctor’s dietary advice, especially to eat a low fat diet, avoid tobacco, and exercise regularly.

If you have the impression that the effect of CADUET tablets is too strong or too weak, talk to your doctor or pharmacist.

Use in children and adolescents

This medication is not recommended for children and adolescents.

If you take more CADUET 10 mg / 10 mg film-coated tablets than you should

If you accidentally take too many CADUET tablets (more than your usual dose), ask your doctor or the nearest hospital for advice. Take any remaining tablets, the carton or the whole carton with you so that hospital staff can quickly identify which medicine you have taken.

If you forget to take CADUET 10 mg / 10 mg film-coated tablets

If you forget to take your dose of CADUET, take your next dose at the normal time.

Do not take a double dose to make up for the dose you forgot to take.

If you stop taking CADUET 10 mg / 10 mg film-coated tablets

Do not stop taking CADUET unless your doctor tells you to.

If you have any further questions on the use of this medicine or want to stop taking your treatment, ask your doctor or pharmacist for more information.

How To Store Caduet?

Keep this medication out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister, the carton and the vial after “EXP”. The expiration date refers to the last day of that month.

Store at a temperature not exceeding 30 ° C.

Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

caduet side effects

The safety of CADUET has been evaluated in double-blind, placebo-controlled studies in 1092 patients treated for concomitant hypertension and dyslipidemia. During clinical trials with CADUET, no specific adverse events specific to this combination were observed.

Adverse events were limited to those previously reported for amlodipine and / or atorvastatin (see table of adverse events below).

In controlled clinical trials, discontinuation of treatment due to clinical adverse events or laboratory abnormalities was observed in 5.1% of patients treated with amlodipine and atorvastatin versus 4.0% of patients treated with amlodipine and atorvastatin. patients taking a placebo.

The adverse events below, listed according to MedDRA system organ classification and frequency order, relate to amlodipine and atorvastatin individually.

Very common: ³ 1/10, common: ³ 1/100 and <1/10, infrequent: ³ 1/1000 and <1/100, rare: ³ 1/10000 and <1/1000, very rare: < 1 / 10,000, frequency not known (cannot be estimated from the available data).

MedDRA

System organ classes

Side effects

Frequency

Amlodipine

Atorvastatin

Infections and infestations

Nasopharyngitis

–

Frequent

Blood and lymphatic system disorders

Leukopenia

Very rare

–

Thrombocytopenia

Very rare

Rare

Immune system disorders

hypersensitivity

Very rare

Frequent

Anaphylaxis

–

Very rare

Metabolism and nutrition disorders

Hyperglycemia *

Very rare

Frequent

Weight gain

Infrequent

Weightloss

Infrequent

–

Hypoglycemia

–

Infrequent

Anorexia

–

Infrequent

Psychiatric disorders

Insomnia

Infrequent

Mood disorders (including anxiety)

Infrequent

–

Nightmares

–

Infrequent

Depression

Infrequent

Frequency not known

Confusion

Rare

–

Disorders of the system nervous

Drowsiness

Frequent

–

Dizziness

Frequent

Infrequent

Headache (especially at the start of treatment)

Frequent

Tremors

Infrequent

–

Hypoesthesias, paresthesias

Infrequent

Syncope

Infrequent

Hypertonia

Very rare

–

Peripheral neuropathy

Very rare

Rare

Amnesia

–

Infrequent

Dysgeusia

Infrequent

Extrapyramidal syndrome

Frequency not known

–

Eye disorders

Blurred vision

–

Infrequent

Visual disturbances (including diplopia)

Infrequent

Rare

Ear and labyrinth disease

Tinnitus

Infrequent

Hearing loss

–

Very rare

Cardiac disorders

Palpitations

Frequent

–

Angina pectoris

Rare

–

Myocardial infarction

Very rare

–

Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)

Very rare

–

Vascular disorders

Flushing

Frequent

–

Hypotension

Infrequent

–

Vasculitis

Very rare

–

Respiratory, thoracic and mediastinal disorders

Pharyngolaryngeal pain

–

Frequent

Epistaxis

–

Frequent

Dyspnea

Infrequent

–

Rhinitis

Infrequent

–

Cough

Very rare

–

Interstitial lung disease, especially during long-term treatment

Frequency not known

Gastrointestinal disorders

Gingival hyperplasia

Very rare

–

Nausea

Frequent

Upper and lower abdominal pain

Frequent

Infrequent

Vomiting

Infrequent

Dyspepsia

Infrequent

Frequent

Changes in intestinal transit (including diarrhea and constipation)

Infrequent

–

Dry mouth

Infrequent

–

Dysgeusia

Infrequent

–

Diarrhea, constipation, gas

–

Frequent

Gastritis

Very rare

–

Pancreatitis

Very rare

Infrequent

Eructation

–

Infrequent

Hepatobiliary disorders

Hepatitis

Very rare

Infrequent

Cholestasis

–

Rare

Jaundice

Very rare

–

Hepatic insufficiency

–

Very rare

Skin and subcutaneous tissue disorders

Bullous dermatosis including erythema multiforme

Very rare

Rare

Angioedema

Very rare

–

Erythema multiforme

Very rare

–

Alopecia

Infrequent

Purpura

Infrequent

–

Skin discoloration

Infrequent

–

Pruritus

Infrequent

Eruption

Infrequent

Hyperhidrosis

Infrequent

–

Exanthema

Infrequent

–

Urticaria

Very rare

Infrequent

Angioneurotic edema

Very rare

Rare

Exfoliative dermatitis

Very rare

–

Photosensitivity

Very rare

–

Stevens-Johnson syndrome

Very rare

Rare

Bullous erythroderma with epidermolysis

–

Rare

Musculoskeletal and connective tissue disorders

Swelling of the joints (including swelling of the ankles)

Frequent

Arthralgia, myalgia

(see section Warnings and precautions for use )

Infrequent

Frequent

Muscle cramps, muscle spasms

Infrequent

Frequent

Back pain

Infrequent

Frequent

Neck pain

–

Infrequent

Pain in extremity

–

Frequent

Muscle fatigue

–

Infrequent

Myositis (see section Warnings and precautions for use )

–

Rare

Rhabdomyolysis, myopathy

(see section Warnings and precautions for use )

–

Rare

Tendinopathies, in rare cases tendon rupture

–

Rare

Immune-mediated necrotizing myopathy

–

Frequency not known

Kidney and urinary tract disorders

Urination disorder, nocturia, pollakiuria

Infrequent

–

Reproductive system and breast disorders

Incapacity

Infrequent

Gynecomastia

Infrequent

Very rare

General disorders and administration site conditions

Edema

Frequent

Infrequent

Peripheral edema

–

Infrequent

Tired

Frequent

Infrequent

Chest pain

Infrequent

Asthenia

Infrequent

Pain

Infrequent

–

Discomfort

Infrequent

Fever

–

Infrequent

Investigations

Increased liver enzymes: alanine aminotransferase, aspartate aminotransferase (mainly related to cholestasis)

Very rare

Frequent

Blood CK increased (see section 4.4 )

–

Frequent

Leukocyturia

–

Infrequent

* Diabetes: The frequency depends on the presence or absence of risk factors (fasting blood sugar ³ 5.6 mmol / l, BMI> 30 kg / m², increased triglyceride levels, history of high blood pressure).

caduet Interactions

Taking other medications

Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Some medicines may interact with CADUET 10 mg / 10 mg film-coated tablets. This interaction may cause one or both of the medicines to be less effective, or on the contrary, this interaction may increase the risk or severity of side effects, including major muscle disorders known as rhabdomyolysis and myopathy (see section 4). .

Some medicines may interact with CADUET 10 mg / 10 mg film-coated tablets:

certain antibiotics such as rifampicin or certain “macrolide” antibiotics such as erythromycin, clarithromycin, telithromycin, fusidic acid or certain drugs used to treat infections caused by fungi such as ketoconazole, itraconazole,

medicines used to regulate lipid levels: fibrates, such as gemfibrozil or colestipol,

medicines used to regulate your heart rhythm, such as amiodarone, diltiazem and verapamil,

medicines used to treat or prevent seizures such as carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone,

medicines used to change how your immune system works, such as cyclosporin

protease inhibitors such as ritonavir, indinavir, nelfinavir used in the treatment of HIV,

medicines used to treat depression, such as nefazodone and imipramine,

medicines used to treat mental disorders, such as neuroleptics,

medicines used to treat heart failure, such as beta blockers

medicines used to treat high blood pressure, such as angiotensin II inhibitors, converting enzyme inhibitors, verapamil and diuretics,

alpha blockers used to treat high blood pressure or prostate problems

other medicines known to interact with CADUET 10 mg / 10 mg film-coated tablets such as ezetimibe (which lowers cholesterol), warfarin (which decreases blood clotting), oral contraceptives, stiripentol (an anticonvulsant used for treatment of epilepsy), cimetidine (used for heartburn and stomach ulcers), phenazone (a pain reliever), antacids (containing aluminum or magnesium, used to relieve problems stomach), and amifostine (used to treat cancer),

sildenafil (used in the treatment of erectile dysfunction, impotence),

dantrolene and baclofen (muscle relaxants),

steroids,

over-the-counter St. John’s Wort products.

CADUET may lower your blood pressure further if you are already taking other medicines to treat your high blood pressure.

If you are taking or have recently taken any other medicines, including medicines obtained without a prescription, talk to your doctor or pharmacist.

INTERACTIONS OF CADUET 10 MG / 10 MG WITH FOOD AND DRINK

Food and drinks

CADUET 10 mg / 10 mg film-coated tablets can be taken at any time of the day, with or without food.

Grapefruit juice

Do not take more than one or two glasses of grapefruit juice per day as large amounts of grapefruit juice may affect the effects of CADUET 10 mg / 10 mg film-coated tablets.

Alcohol

Avoid drinking too much alcohol while taking CADUET 10 mg / 10 mg film-coated tablets. See also section 2 “Take special care with CADUET 10 mg / 10 mg film-coated tablets” for more details.

Drive and use machines

Do not drive or use machines if you feel dizzy after taking this medicine.

Warnings and Precautions

Heart failure

Liver function monitoring

Clinical signs of hepatic dysfunction

Increased transaminases

Heavy alcohol consumption

Hepatic insufficiency

History of liver disease

Predisposing factor to the occurrence of rhabdomyolysis

Subject over 70 years of age

Unexplained muscle pain

Muscle cramp

Muscular weakness

Increase in CPK

Rhabdomyolysis

History of hemorrhagic stroke

History of lacunar infarction

Interstitial lung disease

Risk of diabetes

Woman of childbearing age

Heart failure

Patients with heart failure should be treated with caution. In a long-term placebo-controlled study in patients with severe heart failure (NYHA class III and IV), the reported incidence of pulmonary edema was higher in the amlodipine group compared to the placebo group. (see section Pharmacodynamic properties). Calcium channel blockers including amlodipine should be used with caution in patients with congestive heart failure because they may increase the risk of cardiovascular events and mortality.

Liver effects

Liver function tests should be performed before the start of treatment and then regularly after initiation of treatment, as well as in the event of signs or symptoms suggestive of liver damage. In the event of elevation of the serum transaminase level, monitoring is necessary until normalization.

A persistent increase in ALT or AST exceeding 3 times the upper limit of normal (ULN), should lead to discontinuation of treatment.

The half-life of amlodipine is increased and its AUC (Area Under the Curve) is greater in patients with hepatic impairment; dosage recommendations have not been established.

Due to the presence of atorvastatin, CADUET should be used with caution in patients who consume large amounts of alcohol, in patients with hepatic impairment and / or a history of liver disease.

Muscle effects

Like other HMG-CoA reductase inhibitors, atorvastatin can affect skeletal muscles and lead to myalgia, myositis and myopathies. These muscle damage may rarely progress to rhabdomyolysis, characterized by high levels of creatine kinase (CK) (more than 10 times the ULN), myoglobinemia and myoglobinuria which can lead to kidney failure, and in some cases be fatal.

Regular testing of CK or other muscle enzymes is not recommended in asymptomatic patients treated with statins. However, dosing of CKs is recommended before initiating statin therapy in patients with predisposing factors to rhabdomyolysis as well as in those with muscle symptoms during statin therapy (see below).

Very rare cases of autoimmune-mediated necrotizing myopathies (IMNM) have been reported during or after treatment with certain statins. IMNM is clinically characterized by proximal muscle weakness and increased serum creatine kinase, which persist despite discontinuation of statin therapy.

Before initiation of treatment

CADUET should be prescribed with caution in patients with predisposing factors to rhabdomyolysis. Before starting treatment with a statin, creatine kinase (CK) levels should be checked in the following situations:

Renal failure.

Hypothyroidism.

Personal or family history of genetic muscle diseases.

Personal history of muscle toxicity during treatment with a statin or a fibrate.

History of liver disease and / or excessive alcohol consumption.

In elderly patients (> 70 years), the need for these measures should be assessed, depending on the presence of other factors predisposing to rhabdomyolysis.

Situations in which increased plasma concentrations may occur, due to interactions (see section 4.5) and use in special populations including genetic polymorphisms (see section 5.2). ).

In these situations, a regular reassessment of the benefit / risk of the treatment, as well as regular clinical monitoring is recommended.

If the initial CK level is significantly elevated (more than 5 times the ULN) treatment should not be started.

Creatine kinase measurement

Creatine kinase (CK) should not be measured after heavy exercise or in the presence of another possible cause of increased CK, as this will make interpretation of the results difficult. In the event of a significant elevation of CK (more than 5 times the ULN) before treatment, this should be systematically checked again within 5 to 7 days to confirm the results.

During treatment

It is recommended that patients be asked to promptly report any unexplained muscle pain, muscle cramps or weakness, particularly if accompanied by malaise or fever.

· If symptoms appear when a patient is under treatment with CADUET, a CK levels should be measured; if the CK level is significantly elevated (more than 5 times the ULN), treatment should be discontinued.

· If muscular symptoms are severe and cause daily discomfort, discontinuation of treatment should be considered, even if CK levels did not exceed 5 times the ULN.

· If symptoms resolve and CK levels return to normal, the reintroduction of CADUET may be considered at the lowest dose and under close supervision.

Treatment with CADUET should be discontinued in the event of a clinically significant increase in CK level (> 10 times the ULN) or if rhabdomyolysis is diagnosed or suspected.

Amlodipine has no effect on laboratory parameters.

Combinations with other drugs

As with other statins, the risk of rhabdomyolysis is increased when CADUET is administered in combination with certain drugs which may increase the plasma concentration of atorvastatin, such as strong inhibitors of CYP3A4 or protein transporters (eg, cyclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, determovir and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir, etc / ritonavir). The risk of myopathy may also be increased in combination with gemfibrozil and other fibrates, antivirals used in the treatment of hepatitis C (HCV) (boceprevir, telaprevir, elbasvir / grazoprevir), erythromycin, niacin, l ‘ ezetimibe or colchicine. Therapeutic alternatives (not exhibiting these interactions) should be considered as far as possible.

In the event that the combination of these medicinal products with CADUET is necessary, the benefit / risk of concomitant treatments should be carefully assessed and appropriate clinical monitoring is recommended (see section Interactions with other medicinal products and other forms of interactions).

CADUET should not be administered simultaneously with fusidic acid in systemic form, and for up to 7 days after stopping treatment with fusidic acid. In patients where the use of systemic fusidic acid is considered essential, statin therapy should be discontinued for the duration of fusidic acid therapy. Cases of rhabdomyolysis (some fatal) have been reported in patients receiving fusidic acid and a statin in combination (see section Interactions with other medicinal products and other forms of interactions). Patients should be informed of the need to seek immediate medical attention if they experience symptoms of muscle weakness, pain, or muscle tenderness.

Statin therapy can be restarted seven days after the last dose of fusidic acid.

In exceptional circumstances, when prolonged treatment with systemic fusidic acid is required, e.g. for the treatment of severe infections, the need for co-administration of CADUET and fusidic acid should only be considered in cases of per case and under close medical supervision.

Prevention of stroke by aggressively lowering cholesterol levels (SPARCL study)

In a posteriori analysis performed in subgroups of patients with recent stroke or transient ischemic attack (TIA) but without coronary artery disease, a higher frequency of hemorrhagic stroke was observed in treated patients. per 80 mg atorvastatin compared to patients on placebo.

This high risk is particularly observed in patients who have already had a hemorrhagic stroke or a lacunar infarction at the inclusion of the study.

In patients with a history of hemorrhagic stroke or lacunar infarction, the benefit / risk balance of atorvastatin 80 mg is uncertain. Therefore, the potential risk of occurrence of haemorrhagic stroke should be carefully assessed before any initiation of treatment (see section Pharmacodynamic properties).

Interstitial lung disease

Cases of interstitial lung disease have exceptionally been reported with certain statins, particularly during long-term therapy .

Symptoms may include dyspnea, a non-productive cough, and altered general condition (fatigue, weight loss, and fever). If interstitial lung disease is suspected in a patient, statin therapy should be discontinued.

Diabetes

There is some evidence that statins, as a pharmacological class, increase blood sugar. In some patients at high risk of developing diabetes, statins may cause hyperglycaemia requiring the initiation of diabetes treatment. This risk is nevertheless compensated by the reduction in the vascular risk under statins and therefore it should not be a reason for stopping statins. Patients at risk (fasting blood glucose between 5.6 and 6.9 mmol / l, BMI> 30 kg / m², increased triglyceride levels, arterial hypertension) should be monitored clinically and biologically in accordance with national recommendations.

PREGNANCY & BREAST-FEEDING & FERTILITY

Caduet is contraindicated during pregnancy and lactation.

Women of childbearing age

Women of childbearing potential should use reliable contraceptive measures during treatment ( see Contraindications ).

Pregnancy

The safety of atorvastatin has not been established in pregnant women. No controlled clinical trials have been performed in pregnant women treated with atorvastatin. Following intrauterine exposure to HMG-CoA reductase inhibitors, birth defects have rarely been reported. Studies in animals have shown reproductive toxicity ( see Preclinical safety ).

Treatment of the mother with atorvastatin may reduce the fetal level of mevalonate, which is a precursor of cholesterol biosynthesis. Atherosclerosis is a chronic process, and stopping a lipid-lowering drug during pregnancy should generally have little effect on the long-term risk associated with primary hypercholesterolemia.

For these reasons, Caduet should not be used during pregnancy, or in a woman planning to become pregnant or in whom pregnancy is suspected. Caduet treatment should be withheld during pregnancy or until it has been determined that the woman is not pregnant ( see Contraindications ).

If pregnancy is discovered during treatment, it should be stopped immediately.

Feeding with milk

Amlodipine is excreted in breast milk. The proportion of maternal dose received by the infant has been estimated at an interquartile range of 3-7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. The excretion of atorvastatin or its metabolites in human milk is not known. In rats, the plasma concentrations of atorvastatin and its metabolites are similar to those found in milk ( see Preclinical safety ). Due to the possibility of serious side effects, women treated with Caduet should not breast-feed their infants ( see Contraindications ). Atorvastatin is contraindicated during breastfeeding ( see Contraindications ).

Fertility

No effect of atorvastatin on fertility has been demonstrated in studies conducted in male or female animals ( see Preclinical Safety ).

Reversible biochemical changes in the sperm head have been reported in some patients treated with calcium channel blockers. There is insufficient clinical data regarding the potential effect of amlodipine on fertility. In a study carried out in rats, adverse effects were detected on male fertility ( see Preclinical safety ).

What happens if I overdose from Caduet?

No information is available regarding overdose of Caduet in humans.

Amlodipine:

For amlodipine, experience with intentional overdose in humans is limited. Massive overdose could cause extensive peripheral vasodilation and possibly reflex tachycardia. Marked and possibly prolonged systemic hypotension up to and including shock with fatal outcome has been reported. Any hypotension resulting from acute intoxication requires monitoring in an intensive cardiological care unit. A vasoconstrictor can be used to restore vascular tone and blood pressure. Since amlodipine is highly protein bound, dialysis is unlikely to provide any benefit.

Atorvastatin:

There is no specific treatment for atorvastatin overdose. In the event of overdose, the patient should receive symptomatic treatment and supportive measures should be implemented as needed. Liver function and serum CK concentrations should be monitored. Due to the strong binding of the drug to plasma proteins, hemodialysis is not expected to significantly increase the clearance of atorvastatin.

What should I do if I miss a dose?

If you forget to take CADUET 5/ 10 mg -5/ 10 mg film-coated tablets:

If you forget to take your dose of CADUET, take your next dose at the normal time.

Do not take a double dose to make up for the dose you forgot to take.

What is Forms and Composition ?

SHAPES and PRESENTATIONS

5 mg / 10 mg film-coated tablet (oval, debossed with “Pfizer” on one side and “CDT 051” on the other side; white) and 10 mg / 10 mg (oval, debossed with “Pfizer “On one side and” CDT 101 “on the other side; blue): Boxes of 30 and 90, in blisters.

COMPOSITION

p cpAmlodipine (INN) as amlodipine besilate5 mgor10 mgAtorvastatin (INN) as atorvastatin calcium trihydrate10 mg

Excipients (common): Core: calcium carbonate, croscarmellose sodium, microcrystalline cellulose, pregelatinized corn starch, polysorbate 80, hydroxypropylcellulose, colloidal anhydrous silica, magnesium stearate. Film- coating : 5 mg / 10 mg tablet: Opadry II white 85F28751 (polyvinyl alcohol, titanium dioxide E171, macrogol 3000, talc). 10 mg / 10 mg tablet: Opadry II blue 85F10919 (polyvinyl alcohol, titanium dioxide E171, macrogol 3000, talc, indigo carmine aluminum lake E132).

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

Special warnings:

For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

It treats possible side effects and drug interactions that require attention and its effect on continuous use.

The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

The post caduet tablets Uses, Dosage, Side Effects, Precautions & Warnings appeared first on Drug Online.

from Drug Online https://bit.ly/3lxi9nO via Edrug Online from Faculty of Medicine https://bit.ly/3hIQsGt via Internal Medicine

#medicines #including Allergy Medicines #Anemia #Antibiotic Medicines #Colds & Flu Medicines #Cough Me

0 notes

healthcare-market · 4 years ago

Text

Epistaxis Market to Explore Emerging Trends of Coming Years

Epistaxis is a condition that results in uncertain nose bleeding from either of the nostrils. This clinical condition is usually classified as anterior epistaxis and posterior epistaxis based on the site where the bleeding originates. Epistaxis is rarely life threatening unless it is associated with chronic disorders such as cancer. About 10% of nosebleeds is life threatening, and it is accounted that four of the 2.4 million deaths occur due to epistaxis. This condition commonly occurs in younger children (2-10 years) and older people (50-80 years); however, it is more common among individuals who are above 50 years of age. Prevalence is higher in males (58%) as compared to females (42%). It is usually caused by local trauma, including nasal infection and even nose picking. Environmental factors causing epistaxis include dry climate, lack of humidity in the atmosphere, or prolong inhalation of dry air. People who are on medications such as warfarin, clopidogrel, aspirin, or any other anticoagulant medications are more susceptible to epistaxis. Other predisposing factors such as infection, allergic and non-allergic rhinitis, cocaine snorting, hypertension, alcohol abuse, and inherited bleeding problems also lead to epistaxis.

Read Report Overview: https://www.transparencymarketresearch.com/epistaxis-market.html

In terms of treatment, the global epistaxis market is segmented as topical vasoconstrictors, antibiotic ointments (mupirocin), anesthetics, and nasal cautery. The topical vasoconstrictors segment includes oxymetazoline, co-phenylcaine, or adrenaline, which are applied directly to the mucous membrane. The anesthetics segment includes lidocaine or lignocaine and is often given in combination with vasoconstrictors. Nasal cautery is the most common treatment of epistaxis. Chemical cautery (silver nitrate) and electrocautery (an electrically charged wire such as platinum) are two types of nasal cautery. Chemical cautery is the most popular method for the treatment of idiopathic recurrent epistaxis. Most of the research is focused on device development, thus boosting the growth of the epistaxis market. In 2016, Smith & Nephew launched a range of epistaxis management devices using ‘rapid rhino technology’ that has a blend of carboxymethyl cellulose (CMC), which exhibit self-lubricating properties that provide gentle and even compression to the nasal area and helps in the quicker re-conformation of the nasal anatomy. Additionally, growing incidence rates of epistaxis and chronic diseases boost the growth of the global epistaxis market. The lifelong incidence rate of epistaxis among the general population is about 60%, of which only 10% seeks medical treatment. This factor is projected to restrain the growth of the market during the forecast period.

Request a Sample of Epistaxis Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=35927

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

Enquiry before Buying Epistaxis Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=35927

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

Request For Discount - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=35927

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

Pre-book Epistaxis Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=35927&ltype=S

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/rising-number-of-cancer-related-deaths-and-the-need-for-efficient-treatment-options-to-tackle-the-swelling-fatality-rate-will-aid-in-boosting-the-growth-of-the-radiation-therapy-market-says-tmr-301304147.html

https://www.prnewswire.com/news-releases/increased-number-of-patients-with-hereditary-antithrombin-deficiency-boosts-sales-in-antithrombin-market-tmr-301309026.html

https://www.prnewswire.com/news-releases/developers-of-robotic-technologies-lean-on-safety-and-accuracy-to-boost-patient-outcomes-in-surgical-robots-market-global-valuation-to-touch-us-13-1-bn-by-2022-tmr-301312625.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Transparency Market Research 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com/

0 notes

jayu123-me · 3 years ago

Text

Petroleum Jelly Market – Study On Applications 2031

Petroleum Jelly Market: Introduction

Petroleum Jelly Market: Dynamics

Get Brochure of the Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=72726

Petroleum Jelly Market: Prominent Regions

Request for Covid-19 Impact Analysis :

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=72726

Buy Our Premium Research Report@

https://www.transparencymarketresearch.com/checkout.php?rep_id=72726&ltype=S

Petroleum Jelly Market: Key Players

More Trending Report by Transparency Market Research –

https://www.prnewswire.com/news-releases/yeast-market-to-expand-at-cagr-of-5-3-during-forecast-period-observes-tmr-study-301476718.html

About Us:

Contact

0 notes

thesittingduck · 4 years ago